Dr. Alan Naylor is an independent Drug Discovery consultant and a Medicinal chemist with over 30 years’ experience in Research and Development within GlaxoSmithKline. Alan is also a member of the founding team, and leads the Discovery program at Pathios Therapeutics, an Oxford based Biotechnology company focused on the development of first in class therapies for autoimmune diseases and immuno-oncology.
As an independent consultant, he has been engaged in providing scientific and strategic advice and analysis to major pharma, biotechnology companies, academic groups, capital investment companies and funding bodies on a variety of issues within the drug discovery and healthcare sector. Previously he held the position of Vice President and Director of Medicinal Chemistry within the GSK Drug Discovery organisation. Alan has led strategic, matrix and line management functions with significant international responsibilities. He has an extensive track record of delivery, across a wide range of therapeutic areas, having played a major role in the discovery of over 30 development compounds and is a co-inventor of Serevent, a major advance in the treatment of asthma. Extensive academic interactions have resulted in him being appointed to two visiting chairs at the universities of Reading and Sussex.